ADAP - アダプティミュ―ン・セラピュ―ティクス （Adaptimmune Therapeutics plc）

First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical data with late-stage programs targeting MAGE-A4 and mes…

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022)Med…

Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor RelationsAdrian Rawcliffe - Chief…

Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumorAdaptimmune and GSK agreed term…

Adaptimmune Therapeutics (NASDAQ: ADAP ) reported its Q1 earnings results on Friday, May 12, 2023 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Adaptimmune Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an … Full story available on Benzinga.com

https://www.investing.com/news/pro/adaptimmune-therapeutics-plc-pt-lowered-to-150-at-wells-fargo-432SI-2904746

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc (“Adaptimmune” or the “Company”) (NASDAQ: ADAP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, today announced that Adaptimmune

The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event.

Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q2 2022 Earnings Conference Call Aug 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief…

Adaptimmune Therapeutics (NASDAQ: ADAP ) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus … Full story available on Benzinga.com

Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q2

Adaptimmune (ADAP) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is -$0.29 (-625.0% Y/Y) and the consensus…

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fi…